Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
Silvia Ferrucci, Giovanni Casazza, Luisa Angileri, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 3, pp. 791-791
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review
Ahmad Nader Fasseeh, Baher Elezbawy, Nada Korra, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 12, pp. 2653-2668
Open Access | Times Cited: 68
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management
Marco Caminati, Bianca Olivieri, Annarita Dama, et al.
Expert Review of Respiratory Medicine (2022) Vol. 16, Iss. 7, pp. 713-721
Closed Access | Times Cited: 61
A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis
Masahiro Kamata, Yayoi Tada
JID Innovations (2021) Vol. 1, Iss. 3, pp. 100042-100042
Open Access | Times Cited: 56
Safety of dupilumab in severe atopic dermatitis and infection of Covid‐19: two case reports
Silvia Ferrucci, Maurizio Romagnuolo, Luisa Angileri, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 7
Open Access | Times Cited: 58
Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study
Eustachio Nettis, Silvia Ferrucci, Michela Ortoncelli, et al.
Journal of Investigational Allergology and Clinical Immunology (2020) Vol. 32, Iss. 2, pp. 124-132
Open Access | Times Cited: 54
Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis
Marco Miniotti, Giulia Lazzarin, Michela Ortoncelli, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 5
Open Access | Times Cited: 28
A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities
Dea Metko, Maha Alkofide, Mohannad Abu‐Hilal
JAAD International (2024) Vol. 15, pp. 5-11
Open Access | Times Cited: 5
Cost‐of‐illness of atopic dermatitis in Germany: data from dermatology routine care
Nicole Mohr, Mandy Naatz, L. Zeervi, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 6, pp. 1346-1356
Open Access | Times Cited: 29
Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease
Silvia Ferrucci, Luisa Angileri, Simona Tavecchio, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 5, pp. 2587-2592
Closed Access | Times Cited: 21
Drug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients
Giacomo Dal Bello, Martina Maurelli, Donatella Schena, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 6
Open Access | Times Cited: 31
Adipokines as Biomarkers of Atopic Dermatitis in Adults
Andrzej Jaworek, Jacek C. Szepietowski, Krystyna Szafraniec, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2858-2858
Open Access | Times Cited: 28
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
C.E.M. Griffiths, Marjolein de Bruin‐Weller, Mette Deleuran, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 4, pp. 1357-1372
Open Access | Times Cited: 26
Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration
Yu Wang, Joseph L. Jorizzo
Journal of the American Academy of Dermatology (2021) Vol. 84, Iss. 4, pp. 1010-1014
Closed Access | Times Cited: 25
Factors Associated with Affective Symptoms and Quality of Life in Patients with Atopic Dermatitis
Silvia Ferrucci, Simona Tavecchio, Luisa Angileri, et al.
Acta Dermato Venereologica (2021) Vol. 101, Iss. 11, pp. adv00590-adv00590
Open Access | Times Cited: 24
Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey)
Amy S. Paller, Stephan Weidinger, Korey Capozza, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 4, pp. 961-980
Open Access | Times Cited: 8
Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response
Eustachio Nettis, Silvia Ferrucci, Giovanni Pellacani, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 12
Closed Access | Times Cited: 15
Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study
Eugenio De Corso, Claudio Montuori, Silvia Baroni, et al.
European Archives of Oto-Rhino-Laryngology (2023) Vol. 281, Iss. 5, pp. 2429-2440
Closed Access | Times Cited: 6
Family nursing with the assistance of network improves clinical outcome and life quality in patients underwent coronary artery bypass grafting
Liying Jin, Ruijin Pan, Lihua Huang, et al.
Medicine (2020) Vol. 99, Iss. 50, pp. e23488-e23488
Open Access | Times Cited: 14
Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis
Silvia Ferrucci, Maurizio Romagnuolo, Carlo Alberto Maronese, et al.
Therapeutic Advances in Chronic Disease (2021) Vol. 12
Open Access | Times Cited: 11
The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: A single‐center retrospective study
Ying Li, Jiajing Lu, Rongfen Chen, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 5
Open Access | Times Cited: 8
Blood Cells Count Derived Inflammation Indexes as Predictors of Early Treatment Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Angelo Zinellu, Federica Sucato, Viviana Piras, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2104-2104
Open Access | Times Cited: 4
Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study
Yuqing Hu, Jianzhong Zhang, Yan Zhao
Dermatology (2024) Vol. 240, Iss. 4, pp. 589-596
Closed Access | Times Cited: 1
An Observational Study of Early Treatment Response and Predictors of Dupilumab in the Treatment of Moderate‐to‐Severe Atopic Dermatitis
Sisi Deng, Huan Wang, Jiong Fu, et al.
Dermatologic Therapy (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 1
The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study
Lina U. Ivert, Axel Svedbom, Maria Lundqvist, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00801-adv00801
Open Access | Times Cited: 6
A retrospective case series hypereosinophilia during dupilumab treatment: Hypereosinophilia could be a pharmacogenetic biomarker of dupilumab
Jiyoung Ahn, Joo Yoon Bae, Seong Jun Seo
Dermatologic Therapy (2020) Vol. 33, Iss. 6
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top